S&P 500   4,965.95 (-0.19%)
DOW   38,511.02 (-0.14%)
QQQ   423.58 (-0.88%)
AAPL   181.41 (-0.08%)
MSFT   399.43 (-0.83%)
META   467.50 (-0.80%)
GOOGL   142.18 (+0.75%)
AMZN   167.85 (+0.46%)
TSLA   193.27 (-0.25%)
NVDA   672.72 (-3.14%)
NIO   6.03 (+1.17%)
AMD   163.64 (-1.24%)
BABA   75.75 (+3.57%)
T   16.96 (+0.30%)
F   12.09 (-1.31%)
MU   80.59 (-0.15%)
CGC   3.37 (-4.80%)
GE   148.34 (-0.19%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.81 (-1.40%)
XOM   104.43 (+1.64%)
S&P 500   4,965.95 (-0.19%)
DOW   38,511.02 (-0.14%)
QQQ   423.58 (-0.88%)
AAPL   181.41 (-0.08%)
MSFT   399.43 (-0.83%)
META   467.50 (-0.80%)
GOOGL   142.18 (+0.75%)
AMZN   167.85 (+0.46%)
TSLA   193.27 (-0.25%)
NVDA   672.72 (-3.14%)
NIO   6.03 (+1.17%)
AMD   163.64 (-1.24%)
BABA   75.75 (+3.57%)
T   16.96 (+0.30%)
F   12.09 (-1.31%)
MU   80.59 (-0.15%)
CGC   3.37 (-4.80%)
GE   148.34 (-0.19%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.81 (-1.40%)
XOM   104.43 (+1.64%)
S&P 500   4,965.95 (-0.19%)
DOW   38,511.02 (-0.14%)
QQQ   423.58 (-0.88%)
AAPL   181.41 (-0.08%)
MSFT   399.43 (-0.83%)
META   467.50 (-0.80%)
GOOGL   142.18 (+0.75%)
AMZN   167.85 (+0.46%)
TSLA   193.27 (-0.25%)
NVDA   672.72 (-3.14%)
NIO   6.03 (+1.17%)
AMD   163.64 (-1.24%)
BABA   75.75 (+3.57%)
T   16.96 (+0.30%)
F   12.09 (-1.31%)
MU   80.59 (-0.15%)
CGC   3.37 (-4.80%)
GE   148.34 (-0.19%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.81 (-1.40%)
XOM   104.43 (+1.64%)
S&P 500   4,965.95 (-0.19%)
DOW   38,511.02 (-0.14%)
QQQ   423.58 (-0.88%)
AAPL   181.41 (-0.08%)
MSFT   399.43 (-0.83%)
META   467.50 (-0.80%)
GOOGL   142.18 (+0.75%)
AMZN   167.85 (+0.46%)
TSLA   193.27 (-0.25%)
NVDA   672.72 (-3.14%)
NIO   6.03 (+1.17%)
AMD   163.64 (-1.24%)
BABA   75.75 (+3.57%)
T   16.96 (+0.30%)
F   12.09 (-1.31%)
MU   80.59 (-0.15%)
CGC   3.37 (-4.80%)
GE   148.34 (-0.19%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.81 (-1.40%)
XOM   104.43 (+1.64%)
NYSE:NVRO

Nevro (NVRO) Stock Price, News & Analysis

$16.66
-0.53 (-3.08%)
(As of 12:50 PM ET)
Today's Range
$16.49
$17.29
50-Day Range
$16.27
$22.31
52-Week Range
$13.98
$39.67
Volume
110,604 shs
Average Volume
469,430 shs
Market Capitalization
$603.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Nevro MarketRank™ Stock Analysis

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
44.2% Upside
$24.00 Price Target
Short Interest
Bearish
12.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Nevro in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.81) to ($2.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

Medical Sector

1411th out of 1,856 stocks

Surgical & Medical Instruments Industry

159th out of 190 stocks


NVRO stock logo

About Nevro Stock (NYSE:NVRO)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

NVRO Stock Price History

NVRO Stock News Headlines

NVRO Mar 2024 22.500 call
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Nevro (NYSE:NVRO) Upgraded by StockNews.com to Hold
Nevro (NVRO) Set to Announce Quarterly Earnings on Wednesday
Nevro Corp
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
NVRO Jan 2024 21.500 put
What Analysts Are Saying About Nevro Stock
Nevro Expects Q4 Revenues To Grow 4%, To Lay Off 5% Of Workforce
NVRO Jan 2024 22.000 call
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
Nevro Corp. (NVRO) interactive stock chart – Yahoo Finance
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/21/2024
Next Earnings (Confirmed)
2/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Fax
N/A
Employees
1,087
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$40.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+39.6%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
13 Analysts

Profitability

Net Income
$3 million
Pretax Margin
-23.92%

Debt

Sales & Book Value

Annual Sales
$406.36 million
Book Value
$9.14 per share

Miscellaneous

Free Float
35,119,000
Market Cap
$622.45 million
Optionable
Optionable
Beta
0.94
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Roderick H. MacLeod (Age 57)
    Senior VP & CFO
    Comp: $729.61k
  • Mr. Kashif RashidMr. Kashif Rashid (Age 50)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $703.35k
  • Mr. Kevin R. Thornal (Age 50)
    President, CEO & Director
  • Mr. Richard B. Carter (Age 53)
    Chief Accounting Officer
  • Mr. Christofer Christoforou (Age 54)
    Senior Vice President of Technical Operations
    Comp: $367.4k
  • Geeta Kaveti
    VP and Chief Compliance & Privacy Officer
  • Mr. Jon R. Shear
    Senior Vice President of Corporate Development
  • Meredith Vornholt
    Vice President of Global Marketing
  • Ms. Shana D. Ross M.B.A.
    Senior VP & Chief of Human Resources Officer
  • Dr. David Caraway M.D. (Age 67)
    Ph.D., Senior VP & Chief Medical Officer














NVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price target for 2024?

13 Wall Street analysts have issued 12 month price objectives for Nevro's stock. Their NVRO share price targets range from $15.00 to $40.00. On average, they expect the company's stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2024?

Nevro's stock was trading at $21.52 at the beginning of 2024. Since then, NVRO stock has decreased by 22.7% and is now trading at $16.64.
View the best growth stocks for 2024 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our NVRO earnings forecast
.

How can I listen to Nevro's earnings call?

Nevro will be holding an earnings conference call on Wednesday, February 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its quarterly earnings data on Wednesday, November, 1st. The medical equipment provider reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.12. The medical equipment provider had revenue of $103.86 million for the quarter, compared to analyst estimates of $95.87 million. Nevro had a negative trailing twelve-month return on equity of 33.99% and a negative net margin of 24.22%. Nevro's revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.62) earnings per share.

What ETFs hold Nevro's stock?
What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $116.0 million-$116.0 million, compared to the consensus revenue estimate of $109.3 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.23%), Armistice Capital LLC (8.77%), Braidwell LP (4.91%), Goldman Sachs Group Inc. (2.89%), Palo Alto Investors LP (2.07%) and Principal Financial Group Inc. (1.99%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVRO) was last updated on 2/21/2024 by MarketBeat.com Staff